HeyJaredClinical Trialblazers
Clinical Trialblazers invites you into the world of biotech leaders as they share the untold stories behind their journeys to bring breakthrough innovations to life.
- Indexed episodes, last 90 days
- 3
- Latest publication
- Sep 1, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 7, 2026
Latest episodes
Biotech’s Next Era: Data, AI and the Future of Decision-Making with Jay Roberts (opens the original)
Read excerpt
In this episode of Clinical Trial Blazers, host Alberto Grignolo speaks with veteran biotech executive, investor, and board member Jay Roberts about his journey from CFO to CEO and the leadership lessons that shaped his career. Jay explains how a foundation in finance prepared him to lead biotech companies through clinical uncertainty, capital challenges, and high-stakes decision-making, while emphasizing the importance of building strong teams, making fact-based decisions, and knowing when to p
A Journey through Academia, Big Pharma and Biotech: Building Breakthrough Medicines with Dr. Briggs Morrison (opens the original)
Read excerpt
In this episode of Clinical Trialblazers, host Alberto Grignolo sits down with Dr. Briggs Morrison, CEO of Crossbow Therapeutics and former Chief Medical Officer and Head of Global Medicines Development at AstraZeneca. Briggs shares lessons from a career spanning academia, Big Pharma, and biotech entrepreneurship—including leadership roles at Merck, Pfizer, AstraZeneca, Syndax Pharmaceuticals, and now Crossbow. The conversation explores how small biotech companies drive innovation, why constrain
From Setback to Breakthrough: A CEO’s Journey to a First-in-Class Approval with Reenie McCarthy (opens the original)
Read excerpt
In this episode of Clinical Trialblazers, host Alberto Grignolo sits down with Reenie McCarthy, the CEO of Mighty Therapeutics, formerly known as Stealth BioTherapeutics. Reenie shares her path from venture investor to biotech CEO and the years-long effort to develop and secure approval for a first-in-class therapy targeting mitochondrial dysfunction. She discusses the scientific, regulatory, and funding challenges of advancing a novel treatment through clinical development, as well as the criti
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.